COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA
First Claim
1. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising(a) measuring the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal;
- (b) measuring the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of a healthy control;
(c) comparing the populations measured in steps (a) and (b), and(d) determining that the mammal has a predisposition to the disease if the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal are increased as compared to the healthy control.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota.
-
Citations
119 Claims
-
1. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal; -
(b) measuring the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of a healthy control; (c) comparing the populations measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal are increased as compared to the healthy control. - View Dependent Claims (77, 78, 79)
-
-
2. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal.
-
3. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal.
-
4. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal
-
5. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of the mammal.
-
6. A method of lowering populations of Firmicutes and/or Bacteroidetes in the ileal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
7. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of Firmicutes in the cecal and/or fecal microbiota of the mammal; -
(b) measuring the populations of Firmicutes in the cecal and/or fecal microbiota of a healthy control; (c) comparing the populations measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the populations of Firmicutes in the cecal and/or fecal microbiota of the mammal are increased as compared to the healthy control.
-
-
8. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the ratio of the populations of Firmicutes to the populations of Eubacteria (F/E ratio) in the cecal and/or fecal microbiota of the mammal; -
(b) measuring the F/E ratio in the cecal and/or fecal microbiota of a healthy control; (c) comparing the F/E ratios measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the F/E ratio is increased in the cecal and/or fecal microbiota of the mammal as compared to the healthy control.
-
-
9. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic compostion lowers the populations of Firmicutes in the cecal and/or fecal microbiota of the mammal.
- 10. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the populations of Firmicutes in the cecal and/or fecal microbiota of the mammal.
- 11. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the populations of Firmicutes in the cecal and/or fecal microbiota of the mammal.
-
12. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the populations of Firmicutes in the cecal and/or fecal microbiota of the mammal.
-
13. A method of lowering the populations of Firmicutes in the cecal and/or fecal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
14. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the ratio of the populations of Firmicutes to Eubacteria (F/E ratio) in the cecal and/or fecal microbiota of the mammal.
-
15. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the ratio of the populations of Firmicutes to Eubacteria (F/E ratio) in the cecal and/or fecal microbiota of the mammal.
-
16. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the ratio of the populations of Firmicutes to Eubacteria (F/E ratio) in the cecal and/or fecal microbiota of the mammal.
-
17. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the ratio of the populations of Firmicutes to Eubacteria (F/E ratio) in the cecal and/or fecal microbiota of the mammal.
-
18. A method of lowering the ratio of the populations of Firmicutes to Eubacteria (F/E ratio) in the cecal and/or fecal microbiota of the mammal comprising administering to the mammal a prebiotic composition.
-
19. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of at least one genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of the mammal; -
(b) measuring the populations of the same genus in the intestinal microbiota of a healthy control; (c) comparing the populations measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the populations of at least one genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of the mammal are decreased as compared to the healthy control.
-
- 20. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition stimulates growth or metabolic activity of at least one strain from the genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of the mammal.
- 21. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition stimulates growth or metabolic activity of at least one strain from the genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of the mammal.
-
22. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition stimulates growth or metabolic activity of at least one strain from the genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of the mammal.
-
23. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition stimulates growth or metabolic activity of at least one strain from the genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of the mammal.
-
24. A method of stimulating growth or metabolic activity of at least one strain from the genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS) in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
27. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of at least one taxon selected from the group consisting of Johnsonella, Oscillibacter, Lachnospiraceae, Ruminococcaceae, and Clostridiales in the intestinal microbiota of the mammal; -
(b) measuring the populations of the same taxon in the intestinal microbiota of a healthy control; (c) comparing the populations measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the populations of at least one taxon selected from the group consisting of Johnsonella, Oscillibacter, Lachnospiraceae, Ruminococcaceae, and Clostridiales in the intestinal microbiota of the mammal is increased as compared to the healthy control.
-
- 28. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a composition or a compound, wherein said composition or compound inhibits growth or metabolic activity of at least one strain from the taxon selected from the group consisting of Johnsonella, Oscillibacter, Lachnospiraceae, Ruminococcaceae, and Clostridiales in the intestinal microbiota of the mammal.
- 29. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a composition or a compound, wherein said composition or compound inhibits growth or activity of at least one strain from the taxon selected from the group consisting of Johnsonella, Oscillibacter, Lachnospiraceae, Ruminococcaceae, and Clostridiales in the intestinal microbiota of the mammal.
-
32. A method of inhibiting growth or metabolic activity of at least one strain from the taxon selected from the group consisting of Johnsonella, Oscillibacter, Lachnospiraceae, Ruminococcaceae, and Clostridiales in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
35. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of at least one genus selected from the group consisting of Coprobacillus (C), Sporacetigenium (S), and Holdemania (H), in the intestinal microbiota of the mammal; -
(b) measuring the populations of at least one genus selected from Johnsonella (J) and Oscillibacter (O) in the intestinal microbiota of the mammal; (c) determining a ratio of one of C+S+H, C+H, C+S, S+H, C, S, or H as measured in step (a) to one of J+O, J, or O as measured in step (b), and (d) determining that the mammal has a predisposition to the disease if the ratio in step (c) is below 1, or determining that the mammal has no predisposition to the disease if the ratio in step (c) is above 3.
-
-
36. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), C+H, C+S, S+H, or C+S+H to populations of one of (b) Johnsonella (J), Oscillibacter (O), or J+O to above 3 in the intestinal microbiota of the mammal.
-
37. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), C+H, C+S, S+H, or C+S+H to populations of one of (b) Johnsonella (J), Oscillibacter (O), or J+O to above 3 in the intestinal microbiota of the mammal.
-
38. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), C+H, C+S, S+H, or C+S+H to populations of one of (b) Johnsonella (J), Oscillibacter (O), or J+O to above 3 in the intestinal microbiota of the mammal.
-
39. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), C+H, C+S, S+H, or C+S+H to populations of one of (b) Johnsonella (J), Oscillibacter (O), or J+O to above 3 in the intestinal microbiota of the mammal.
-
40. A method of increasing the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), C+H, C+S, S+H, or C+S+H to populations of one of (b) Johnsonella (J), Oscillibacter (O), or J+O in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
41. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of at least one genus selected from the group consisting of Coprobacillus (C), Sporacetigenium (S), Holdemania (H), Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), and Clostridium cocleatum (Cc) in the intestinal microbiota of the mammal; -
(b) measuring the populations of Firmicutes (F) in the intestinal microbiota of the mammal; (c) determining a ratio of one of C+S+H, C+H, C+S, S+H, C, S, H, EIS, PIS, or Cc as measured in step (a) to F as measured in step (b), and (d) determining that the mammal has a predisposition to the disease if the ratio in step (c) is below 0.1, or determining that the mammal has no predisposition to the disease if the ratio in step (c) is above 0.1.
-
-
42. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), C+H, C+S, S+H, or C+S+H to populations of (b) Firmicutes (F) to above 0.1 in the intestinal microbiota of the mammal.
-
43. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), C+H, C+S, S+H, or C+S+H to populations of (b) Firmicutes (F) to above 0.1 in the intestinal microbiota of the mammal.
-
44. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), C+H, C+S, S+H, or C+S+H to populations of (b) Firmicutes (F) to above 0.1 in the intestinal microbiota of the mammal.
-
45. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), C+H, C+S, S+H, or C+S+H to populations of (b) Firmicutes (F) to above 0.1 in the intestinal microbiota of the mammal.
-
46. A method of increasing the ratio of populations of one of (a) Coprobacillus (C), Sporacetigenium (S), Holdemania (H), Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), C+H, C+S, S+H, or C+S+H to populations of (b) Firmicutes (F) in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
47. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of at least one family selected from Erysipelotrichaceae and Peptostreptococcacea, in the intestinal microbiota of the mammal; -
(b) measuring the populations of at least one family selected from Lachnospiraceae and Ruminococcaceae in the intestinal microbiota of the mammal; (c) determining a ratio of one of Erysipelotrichaceae+Peptostreptococcacea, Erysipelotrichaceae, or Peptostreptococcacea as measured in step (a) to one of Lachnospiraceae+Ruminococcaceae, Lachnospiraceae, or Ruminococcaceae as measured in step (b), and (d) determining that the mammal has a predisposition to the disease if the ratio in step (c) is below 0.1, or determining that the mammal has no predisposition to the disease if the ratio in step (c) is above 0.1.
-
-
48. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae+Peptostreptococcacea, Erysipelotrichaceae, or Peptostreptococcacea to populations of one of (b) Lachnospiraceae+Ruminococcaceae, Lachnospiraceae, or Ruminococcaceae to above 0.1 in the intestinal microbiota of the mammal
-
49. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae+Peptostreptococcacea, Erysipelotrichaceae, or Peptostreptococcacea to populations of one of (b) Lachnospiraceae+Ruminococcaceae, Lachnospiraceae, or Ruminococcaceae to above 0.1 in the intestinal microbiota of the mammal.
-
50. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae+Peptostreptococcacea, Erysipelotrichaceae, or Peptostreptococcacea to populations of one of (b) Lachnospiraceae+Ruminococcaceae, Lachnospiraceae, or Ruminococcaceae to above 0.1 in the intestinal microbiota of the mammal.
-
51. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae+Peptostreptococcacea, Erysipelotrichaceae, or Peptostreptococcacea to populations of one of (b) Lachnospiraceae+Ruminococcaceae, Lachnospiraceae, or Ruminococcaceae to above 0.1 in the intestinal microbiota of the mammal.
-
52. A method of increasing the ratio of populations of one of (a) Erysipelotrichaceae+Peptostreptococcacea, Erysipelotrichaceae, or Peptostreptococcacea to populations of one of (b) Lachnospiraceae+Ruminococcaceae, Lachnospiraceae, or Ruminococcaceae in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
- 80. A probiotic composition comprising one or more strains from the genus selected from the group consisting of Coprobacillus, Sporacetigenium, Holdemania, Dorea, Blautia, Enterococcus, Erysipelotrichaceae Incertae Sedis (EIS), Clostridium cocleatum, and Peptosteptococcaceae IS (PIS).
-
93. A probiotic composition comprising one or more strains from the genus Holdemania and one or more compounds selected from the group consisting of Tween 80, esculin, fructose, glucose, lactose, maltose, salicin, and sucrose.94. A probiotic composition comprising one or more strains from the genus Sporoacetigenicum and one or more compounds selected from the group consisting of arabinose, fructose, glucose, maltose, and xylose.
-
95. A probiotic composition comprising one or more strains from the genus Coprobacillus and one or more compounds selected from the group consisting of mannose, fructose, sucrose, maltose, cellobiose, trehalose, salicin, lactose, glucose, and galactose.
-
96. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the total number of Butyryl CoA transferase (BCoAT)-encoding genes in the intestinal microbiota of the mammal; -
(b) measuring the total number of BCoAT-encoding genes in the intestinal microbiota of a healthy control; (c) comparing the total number of BCoAT-encoding genes measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the total number of BCoAT-encoding genes in the intestinal microbiota of the mammal is increased as compared to the healthy control. - View Dependent Claims (97)
-
-
98. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring a ratio of the total number of Butyryl CoA transferase (BCoAT)-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of the mammal; -
(b) measuring a ratio of the total number of BCoAT-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of a healthy control; (c) comparing the ratios of the total number of BCoAT-encoding genes to copies of Bacteroidetes 16S rRNA measured in steps (a) and (b), and (d) determining that the mammal has a predisposition to the disease if the ratio of the total number of BCoAT-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of the mammal is increased as compared to the healthy control. - View Dependent Claims (99)
-
- 100. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the levels of Butyryl CoA transferase (BCoAT) enzyme and/or the levels of butyrate in the intestinal microbiota of the mammal.
-
101. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the levels of Butyryl CoA transferase (BCoAT) enzyme and/or the levels of butyrate in the intestinal microbiota of the mammal.
-
102. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the levels of Butyryl CoA transferase (BCoAT) enzyme and/or the levels of butyrate in the intestinal microbiota of the mammal.
-
103. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the levels of Butyryl CoA transferase (BCoAT) enzyme and/or the levels of butyrate in the intestinal microbiota of the mammal
-
104. A method of lowering the levels of Butyryl CoA Transferase (BcoAT) enzyme and/or the levels of butyrate in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
- 107. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the ratio of the total number of Butyryl CoA transferase (BCoAT)-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of the mammal.
-
108. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition lowers the ratio of the total number of Butyryl CoA transferase (BCoAT)-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of the mammal.
-
109. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the ratio of the total number of Butyryl CoA transferase (BCoAT)-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of the mammal.
-
110. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition lowers the ratio of the total number of Butyryl CoA transferase (BCoAT)-encoding genes to copies of Bacteroidetes 16S rRNA in the intestinal microbiota of the mammal.
-
111. A method of lowering the ratio of the total number of Butyryl CoA Transferase (BcoAT)- encoding genes to copies of bacteroidetes 16S rRNA in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
113. A method for diagnosing predisposition to a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising
(a) measuring the populations of at least one genus selected from the group consisting of Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), and Clostridium cocleatum (Cc) in the intestinal microbiota of the mammal; -
(b) measuring the populations of Johnsonella (J) in the intestinal microbiota of the mammal; (c) determining a ratio of one of EIS, PIS, EIS+PIS, or Cc as measured in step (a) to J as measured in step (b), and (d) determining that the mammal has a predisposition to the disease if the ratio in step (c) is below 1, or determining that the mammal has no predisposition to the disease if the ratio in step (c) is above 1.
-
-
114. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), or EIS+PIS to populations of (b) Johnsonella (J) to above 1 in the intestinal microbiota of the mammal
-
115. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition, wherein said probiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), or EIS+PIS to populations of (b) Johnsonella (J) to above 1 in the intestinal microbiota of the mammal.
-
116. A method for promoting weight loss in a mammal comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), or EIS+PIS to populations of (b) Johnsonella (J) to above 1 in the intestinal microbiota of the mammal.
-
117. A method for preventing or treating a disease in a mammal selected from the group consisting of obesity, metabolic syndrome, diabetes mellitus, insulin-deficiency related disorders, insulin-resistance related disorders, glucose intolerance, non-alcoholic fatty liver, abnormal lipid metabolism, and atherosclerosis, said method comprising administering to the mammal a therapeutically effective amount of a prebiotic composition, wherein said prebiotic composition increases the ratio of populations of one of (a) Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), or EIS+PIS to populations of (b) Johnsonella (J) to above 1 in the intestinal microbiota of the mammal.
-
118. A method of increasing the ratio of populations of one of (a) Erysipelotrichaceae Incertae Sedis (EIS), Peptostreptococcaceae Incertae Sedis (PIS), Clostridium cocleatum (Cc), or EIS+PIS to populations of (b) Johnsonella (J) in the intestinal microbiota of a mammal comprising administering to the mammal a prebiotic composition.
-
119. A probiotic composition comprising one or more strains from the genus Clostridium cocleatum and one or more compounds selected from the group consisting of cellobiose, fructose, galactose, glucose, inulin, lactose, maltose, mannose, mellibiose, raffinose, and sucrose.
Specification